drugset / Trial / NCT01357642

Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

NCT01357642

Phase 3 Completed 373 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in comparison to a Placebo-HFA control MDI and the currently marketed Primatene® Mist (epinephrine CFC inhaler), in adolescent and adult subjects with asthma.

Timeline

Start
2011-07
Primary completion
2011-11
Completion
2011-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 0.125 mg Inhaled
Subject Epinephrine Other / unclassified 0.22 mg Inhaled

Indications